Plus Therapeutics announced it will change its name to Cerenome and trade under the new Nasdaq ticker CNSY starting August 3, 2026. The company affirmed its 2026 guidance, focusing on advancing its CNS cancer therapeutic REYOBIQ and expanding its CNSide Diagnostics platform, which has significantly grown payer coverage and physician adoption. Key milestones include progressing clinical trials for REYOBIQ, scaling commercial manufacturing, and expanding CNSide's diagnostic tests and Medicare reimbursement. The rebranding reflects the company's integrated approach combining therapeutics, diagnostics, and AI to improve CNS cancer patient outcomes.
Target is launching "Picolette," an exclusive baby collection by Olivia Culpo, featuring 60 stylish and affordable items to boost its baby product segment. The collection will be available in about 1,400 stores and online starting July 26, enhancing ...
Votito has launched a new product management platform designed to help small software teams decide what products to build by combining user feedback with product research. As AI tools make software development faster, the challenge shifts to understa...
Investar Holding Corporation reported strong Q2 2026 results, with earnings per share of $0.75, beating analyst estimates by 7.14%. Quarterly revenue reached $36.55 million, a 64.1% increase year-over-year, surpassing expectations. The company has co...
Personalis, a cancer testing firm, is being acquired by Tempus AI in a $1.5 billion all-stock deal offering $16.25 per share, a 28% premium. Despite the premium, Personalis shares dropped 13.39% on the announcement day due to capped upside until deal...
Dynex Capital reported strong Q2 2026 financial results with revenue of $277.13 million, far exceeding analyst expectations of $103.62 million. Although earnings per share slightly missed estimates at $0.36 versus $0.37 expected, the company expanded...
